Possible role of dimethylarsinous acid in dimethylarsinic acid-induced urothelial toxicity and regeneration in the rat

被引:122
作者
Cohen, SM [1 ]
Arnold, LL
Uzvolgyi, E
Cano, M
John, MS
Yamamoto, S
Lu, XF
Le, XC
机构
[1] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Nebraska Med Ctr 983135, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Nebraska Med Ctr 983135, Omaha, NE 68198 USA
[3] Univ Alberta, Dept Environm Hlth Sci, Edmonton, AB T6G 2G3, Canada
关键词
D O I
10.1021/tx020026z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dimethylarsinic acid (DMA(V)) is carcinogenic to the rat urinary bladder when administered at high doses in the diet or drinking water. At a dietary dose of 100 ppm (mug/g), it produces cytotoxicity within 6 h and increased proliferation (hyperplasia) by 7 days of administration. We hypothesize that formation of the reactive organic intermediate dimethylarsinous acid (DMA(III)) is involved in the induction of the cytotoxicity. To evaluate the possibility that DMA(v) administration produces urothelial toxicity and regeneration by the formation of trivalent arsenicals, 2,3-dimercaptopropane-1-sulfonic acid (DMPS, 5600 ppm), a chelator of trivalent arsenicals, was co-administered with DMA(V) (100 ppm) for 2 weeks to groups of female Fischer F344 rats. Based on light and scanning electron microscopy, and bromodeoxyuridine labeling index, DMA(V) produced cytotoxicity and regenerative hyperplasia of the urothelium. which was inhibited by co-administration with DMPS. The major forms of arsenic in the 24-h urine of rats administered DMA(v) were high concentrations of DMA(v) (66.4 +/- 2.7 muM) itself and the pentavalent organic arsenical trimethylarsine oxide (TMAO) (73.2 +/- 9.5 muM). Co-administration with DMPS led to an increase in DMA(v) (507 +/- 31 muM) with a decrease in TMAO (2.8 +/- 0.4 muM) excretion. The formation of TMAO from DMA(v) mechanistically suggests formation of the intermediate trivalent metabolite, In a second experiment evaluating fresh void urines collected on study days 1, 71, and 175, we detected DMA(III) in the urine of DMA(v) and DMA(v) plus DMPS-treated rats at approximately micromolar concentrations. Using rat (MYP3) and human (1T1) urothelial cells, cytotoxicity for trivalent arsenicals, sodium arsenite, monomethylarsonous acid (MMA(III)), and DMA(III) was demonstrated at 0.4 +/- 4.8 muM concentrations, whereas MMA(v), DMA(v), and TMAO were cytotoxic at millimolar concentrations. The presence of DMA(III) at micromolar concentrations in the urine of rats fed 100 ppm DMA(v) suggests that DMA(III) produced in vivo may be involved in the toxic effects in the rat urinary bladder after dietary administration of DMA(V).
引用
收藏
页码:1150 / 1157
页数:8
相关论文
共 34 条
[21]   Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India [J].
Mandal, BK ;
Ogra, Y ;
Suzuki, KT .
CHEMICAL RESEARCH IN TOXICOLOGY, 2001, 14 (04) :371-378
[22]   BIOTRANSFORMATION OF DIMETHYLARSINIC ACID IN MOUSE, HAMSTER AND MAN [J].
MARAFANTE, E ;
VAHTER, M ;
NORIN, H ;
ENVALL, J ;
SANDSTROM, M ;
CHRISTAKOPOULOS, A ;
RYHAGE, R .
JOURNAL OF APPLIED TOXICOLOGY, 1987, 7 (02) :111-117
[23]  
MARTIN RA, 1984, J AM COLL TOXICOL, V3, P1
[24]   Methylated trivalent arsenic species are genotoxic [J].
Mass, MJ ;
Tennant, A ;
Roop, BC ;
Cullen, WR ;
Styblo, M ;
Thomas, DJ ;
Kligerman, AD .
CHEMICAL RESEARCH IN TOXICOLOGY, 2001, 14 (04) :355-361
[25]   Monomethylarsonous acid (MMAIII) is more toxic than arsenite in Chang human hepatocytes [J].
Petrick, JS ;
Ayala-Fierro, F ;
Cullen, WR ;
Carter, DE ;
Aposhian, HV .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2000, 163 (02) :203-207
[26]  
ROSSMAN TG, 1998, ENV TOXICOLOGY CURRE, P171
[27]  
*SAS I, SAS STAT US GUID STA, V2
[28]   Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells [J].
Styblo, M ;
Del Razo, LM ;
Vega, L ;
Germolec, DR ;
LeCluyse, EL ;
Hamilton, GA ;
Reed, W ;
Wang, C ;
Cullen, WR ;
Thomas, DJ .
ARCHIVES OF TOXICOLOGY, 2000, 74 (06) :289-299
[29]  
Tamatani T, 1999, INT J ONCOL, V15, P743
[30]  
TILTMAN AJ, 1972, J NATL CANCER I, V48, P125